<?xml version="1.0" encoding="ASCII"?>
<biogps><data><item key="owner">ArrayExpress Uploader</item><item key="ownerprofile_id">arrayexpress_sid</item><item key="species">human</item><item key="factors"><item><item key="GSM897018"><item key="CELL LINE">epithelioid sarcoma VA-ES-BJ cells</item><item key="COMPOUND">Trail</item></item></item><item><item key="GSM897017"><item key="CELL LINE">epithelioid sarcoma VA-ES-BJ cells</item><item key="COMPOUND">Taurolidine</item></item></item><item><item key="GSM897016"><item key="CELL LINE">epithelioid sarcoma VA-ES-BJ cells</item><item key="COMPOUND">Trail and Taurolidine</item></item></item><item><item key="GSM897015"><item key="CELL LINE">epithelioid sarcoma VA-ES-BJ cells</item><item key="COMPOUND">untreated</item></item></item><item><item key="GSM897014"><item key="CELL LINE">leiomyosarcoma SK-LMS-1 cells</item><item key="COMPOUND">Trail</item></item></item><item><item key="GSM897013"><item key="CELL LINE">leiomyosarcoma SK-LMS-1 cells</item><item key="COMPOUND">Taurolidine</item></item></item><item><item key="GSM897012"><item key="CELL LINE">leiomyosarcoma SK-LMS-1 cells</item><item key="COMPOUND">Trail and Taurolidine</item></item></item><item><item key="GSM8970"><item key="CELL LINE">leiomyosarcoma SK-LMS-1 cells</item><item key="COMPOUND">untreated</item></item></item><item><item key="GSM897010"><item key="CELL LINE">rhabdomyosacrcoma A-204 cells</item><item key="COMPOUND">Trail</item></item></item><item><item key="GSM897009"><item key="CELL LINE">rhabdomyosacrcoma A-204 cells</item><item key="COMPOUND">Taurolidine</item></item></item><item><item key="GSM897008"><item key="CELL LINE">rhabdomyosacrcoma A-204 cells</item><item key="COMPOUND">Trail and Taurolidine</item></item></item><item><item key="GSM897007"><item key="CELL LINE">rhabdomyosacrcoma A-204 cells</item><item key="COMPOUND">untreated</item></item></item></item><item key="id">2505</item><item key="pop_total">0</item><item key="platform">4</item><item key="summary_wrapped">Microarray analysis revealed differential gene expression patterns of rhabdomyosarcoma (A-204), leiomyosarcoma (SK-LMS-1) and epithelioid...</item><item key="geo_gse_id">E-GEOD-36572</item><item key="owner_profile">/profile/8773/arrayexpressuploader</item><item key="factor_count">2</item><item key="sample_count">12</item><item key="tags"><item>carcinoma</item><item>cell</item><item>epithelioid cell</item><item>epithelioid cell sarcoma</item><item>leiomyosarcoma</item><item>rhabdomyosarcoma</item><item>sarcoma</item></item><item key="lastmodified">Dec.12, 2014</item><item key="is_default">False</item><item key="geo_gds_id"/><item key="slug">synergistic-effects-of-trail-and-taurolidine-on-so</item><item key="geo_id_plat">E-GEOD-36572_A-AFFY-44</item><item key="name">Synergistic effects of TRAIL and taurolidine on soft tissue sarcoma cell lines</item><item key="created">Jul.12, 2014</item><item key="summary">Microarray analysis revealed differential gene expression patterns of rhabdomyosarcoma (A-204), leiomyosarcoma (SK-LMS-1) and epithelioid cell sarcoma (VA-ES-BJ) cells treated with TRAIL and/or taurolidine. To explore new therapeutic options in the treatment of sarcomas, we tested the antibiotic taurolidine (TRD) on A-204, SK-LMS-1 and VA-ES-BJ carcinoma cell lines alone and in combination with rhTRAIL (TNF related apoptosis-inducing ligand). Gene expression was analysed by RNA microarray. Cell lines were treated with Taurolidine, Trail and a combination of both and compaired to untreated cells</item><item key="source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-36572</item><item key="sample_source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-36572/samples/</item></data></biogps>
